



ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodara 390 003
AUDITED FINANCIAL RESULTS
FOR THE YEAR ENDED 31st MARCH, 2014

Rs. in lacs

	Particulars	STANDALONE				
		Quarter Ended			Year Ended	
		March-14	December-13	March-13	March-14	March-13
	PART- I	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
1	(a) Net Sales / Income from Operations					
	Domestic	24,536	27,190	23,382	104,106	99,712
	Exports	21,092	20,579	14,419	80,793	50,117
	Total	45,628	47,769	37,801	184,899	149,829
	Less : Excise Duty	189	187	178	771	875
	Net Sales / Income from Operations	45,439	47,582	37,623	184,128	148,954
	(b) Other Operating Income	70	78	150	251	309
	Total Income from Operations	45,509	47,660	37,773	184,379	149,263
2	Expenses					
	(a) Decrease/(increase) in stock in trade and work in progress	407	(2,424)	2,550	(4,065)	2,134
	(b) Consumption of Raw Materials & Packing Materials	13,088	15,144	10,810	55,593	47,030
	(c) Purchase of traded goods	4,128	4,799	3,348	19,807	16,559
	(d) Employees' Cost	6,677	6,202	5,077	24,446	19,379
	(e) Marketing Expense	2,934	3,958	2,576	16,075	13,350
	(f) Research and Development Expense	2,593	2,727	2,200	10,510	7,363
	(g) Excise Duty	62	76	171	425	100
	(h) Other Expenditure	6,955	6,860	4,870	25,686	18,972
	Total Expenses	36,844	37,342	31,602	148,477	124,887
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	8,665	10,318	6,171	35,902	24,376
4	Other Income	277	20	7	319	393
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	8,942	10,338	6,178	36,221	24,769
6	Depreciation	1,099	1,012	864	4,049	3,496
7	Interest (Net)	229	348	183	981	1,457
8	Net Profit / (Loss) from Ordinary Activities before Tax	7,614	8,978	5,131	31,191	19,816
9	Tax Expense					
	Less : Provision for Current Tax	1,752	1,882	1,024	6,700	3,975
	Less /Add : Provision for Deferred Tax Liability/(Assets)	148	312	136	663	96
10	Net Profit / (Loss) from Ordinary Activities after Tax	5,714	6,784	3,971	23,828	15,745
11	Paid up Equity Share Capital (Face value of share Rs. 2/-)	3,770	3,770	3,770	3,770	3,770
12	Reserves excluding Revaluation Reserve	-	-	-	59,199	42,206
13	Basic & Diluted EPS (Not Annualised)	3.03	3.60	2.11	12.64	8.35
	PART- II					
A	Particulars of Shareholding					
1	Public Shareholding					
	- Number of Shares	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding					
	- Fully Non - Encumbered					
	- Number of Shares	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 31st March, 2014				
	Pending at the beginning of the quarter	NIL				
	Received during the quarter	7				
	Disposed of during the quarter	7				
	Remaining unresolved at the end of the quarter	NIL				



ALEMBIC PHARMACEUTICALS LIMITED
 Regd. Office: Alembic Road, Vadodara 390 003
AUDITED FINANCIAL RESULTS
FOR THE YEAR ENDED 31st MARCH, 2014

Rs. in Lacs

Particulars	CONSOLIDATED				
	Quarter Ended			Year Ended	
	March-14	December-13	March-13	March-14	March-13
	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
PART- I					
1 (a) Net Sales / Income from Operations					
Domestic	24,536	27,190	23,382	104,106	99,712
Exports	21,986	21,484	14,454	82,735	52,888
Total	46,522	48,674	37,836	186,841	152,600
Less : Excise Duty	189	187	178	771	875
Net Sales / Income from Operations	46,333	48,487	37,658	186,070	151,725
(b) Other Operating Income	70	78	150	251	309
Total Income from Operations	46,403	48,565	37,808	186,321	152,034
2 Expenses					
(a) Decrease/(increase) in stock in trade and work in progress	407	(2,424)	2,550	(4,065)	2,134
(b) Consumption of Raw Materials & Packing Materials	13,088	15,144	10,810	55,593	47,030
(c) Purchase of traded goods	4,128	4,799	3,348	19,807	18,906
(d) Employees' Cost	6,715	6,418	5,077	24,700	19,379
(e) Marketing Expense	3,088	4,346	2,576	16,618	13,350
(f) Research and Development Expense	3,120	2,901	2,267	11,643	7,430
(g) Excise Duty	62	76	171	425	100
(h) Other Expenditure	6,666	7,082	4,451	25,829	18,509
Total Expenses	37,274	38,342	31,250	150,550	126,838
3 Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	9,129	10,223	6,558	35,771	25,196
4 Other Income	277	20	7	319	393
5 Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	9,406	10,243	6,565	36,090	25,589
6 Depreciation	1,099	1,012	864	4,049	3,497
7 Interest (Net)	229	348	183	981	1,457
8 Net Profit / (Loss) from Ordinary Activities before Tax	8,078	8,883	5,518	31,060	20,635
9 Tax Expense					
Less : Provision for Current Tax	1,801	1,978	1,017	6,847	4,014
Less/(Add) : Provision for Deferred Tax Liability /(Assets)	148	312	136	663	96
10 Net Profit / (Loss) from Ordinary Activities after Tax	6,129	6,593	4,365	23,550	16,525
11 Paid up Equity Share Capital (Face value of share ₹ 2/-)	3,770	3,770	3,770	3,770	3,770
12 Reserves excluding Revaluation Reserve	-	-	-	63,787	46,524
13 Basic & Diluted EPS (Not Annualised)	3.25	3.50	2.32	12.49	8.77
PART- II					
A Particulars of Shareholding					
1 Public Shareholding					
- Number of Shares	48777294	48777294	48777294	48777294	48777294
- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
2 Promoters and Promoter Group Shareholding					
- Fully Non - Encumbered					
- Number of Shares	139738620	139738620	139738620	139738620	139738620
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
B INVESTOR COMPLAINTS					
Pending at the beginning of the quarter			NIL		
Received during the quarter			7		
Disposed of during the quarter			7		
Remaining unresolved at the end of the quarter			NIL		

Notes :

- 1 The above results, have been duly audited by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors. The results include duly audited financial statement of Company's Subsidiary Alembic Global Holding SA (AGH) and its step down subsidiaries. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Board has recommended dividend of Equity Shares at Rs 3.00 per share i.e 150% for the year ended on 31.03.2014 (P Y Rs. 2.50 per share)
- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 28th April, 2014

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com